Goat F(ab')2 Anti-Human Ig-PE
Referencia 2012-09
embalaje : 0.25mg
Marca : Southern Biotech
Contact local distributor :
Teléfono : +1 850 650 7790
| Isotype | Goat F(ab')2 IgG |
|---|---|
| Isotype Control | Goat F(ab')2 IgG-PE |
| Specificity | Reacts with the heavy and light chains of human IgG, IgM, and IgA |
| Source | Pepsin digest of Goat Anti-Human Ig (SB Cat. No. 2010) |
| Cross Adsorption | None; may react with immunoglobulins from other species |
| Conjugate | PE (R-phycoerythrin) |
| Buffer Formulation | Phosphate buffered saline containing < 0.1% sodium azide and a stabilizer |
| Clonality | Polyclonal |
| Concentration | 0.25 mg/mL |
| Volume | 1.0 mL |
| Recommended Storage | 2-8°C; Avoid exposure to light; Do not freeze |
| Applications | Quality tested applications for relevant formats include - ELISA 1,2,5 FLISA Flow Cytometry 7,8 Other referenced applications for relevant formats include - ELISpot 3,4 Immunohistochemistry-Frozen Sections 6 Stimulation 9,10 |
| RRID Number | AB_2795575 |
Documentation
Technical Bulletin Safety Datasheet
Certificate of Analysis Lookup
Enter the Catalog Number and Lot Number for the Certificate of Analysis you wish to view
- 1. Kozlowski PA, Chen D, Eldridge JH, Jackson S. Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals. AIDS Res Hum Retroviruses. 1994;10:813-22. (ELISA)
- 2. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA. 2006;103:17408-13. (ELISA)
- 3. Sira MM, Yoshida T, Takeuchi M, Kashiwayama Y, Futatani T, Kanegane H, et al. A novel immunoregulatory protein in human colostrum, syntenin-1, for promoting the development of IgA-producing cells from cord blood B cells. Int Immunol. 2009;21:1013-23. (ELISpot)
- 4. Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11(4):R123. (ELISpot)
- 5. White CA, Pone EJ, Lam T, Tat C, Hayama KL, Li G, et al. Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses. J Immunol. 2014;193:5933-50. (ELISA)
- 6. Xu W, He B, Chiu A, Chadburn A, Shan M, Buldys M, et al. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol. 2007;8:294-303. (IHC-FS)
- 7. Heile JM, Fong Y, Rosa D, Berger K, Saletti G, Campagnoli S, et al. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates. J Virol. 2000;74:6885-92. (FC)
- 8. Bao G, Li Y, Ma Q, He X, Xing J, Yang X, et al. Isolating human antibody against human hepatocellular carcinoma by guided-selection. Cancer Biol Ther. 2005;4:1374-80. (FC)
- 9. Liubchenko GA, Appleberry HC, Striebich CC, Franklin KE, Derber LA, Holers VM, et al. Rheumatoid arthritis is associated with signaling alterations in naturally occurring autoreactive B-lymphocytes. J Autoimmun. 2013;40:111-21. (Stim)
- 10. Lyubchenko T, Zerbe GO. B cell receptor signaling-based index as a biomarker for the loss of peripheral immune tolerance in autoreactive B cells in rheumatoid arthritis. PLoS One. 2014;9(7):e102128. (Stim)